Evidence map›Paper›PMID 37231229›Full record

ArticleEJNMMI research2023

Imaging quality of an artificial intelligence denoising algorithm: validation in

Charles Margail, Charles Merlin, Tommy Billoux, Maxence Wallaert, Hosameldin Otman, Nicolas Sas, Ioana Molnar, Florent Guillemin, Louis Boyer, Laurent Guy and 5 more

Abstract read
In one paragraph

Article in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Superiority of long axial field-of-viewEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Charles MargailNuclear Medicine, CLCC Jean Perrin: Centre Jean Perrin, Clermont-Ferrand, France. charles.margail@clermont.unicancer.fr.ORCID http://orcid.org/0000-0002-7233-8719
Charles MerlinNuclear Medicine, CLCC Jean Perrin: Centre Jean Perrin, Clermont-Ferrand, France.
Tommy BillouxInserm UMR 1240 IMOST, Physique Médicale, CLCC Jean Perrin, Université Clermont Auvergne, Clermont-Ferrand, France.
Maxence WallaertIncepto Medical, Paris, France.
Hosameldin OtmanNuclear Medicine, CLCC Jean Perrin: Centre Jean Perrin, Clermont-Ferrand, France.
Nicolas SasInserm UMR 1240 IMOST, Physique Médicale, CLCC Jean Perrin, Université Clermont Auvergne, Clermont-Ferrand, France.
Ioana MolnarBiostatistics, CLCC Jean Perrin, Clermont-Ferrand, France.
Florent GuilleminRadiotherapy, CLCC Jean Perrin, Clermont-Ferrand, France.
Louis BoyerRadiology, UMR 6602 UCA/CNRS/SIGMA, Hôpital Gabriel-Montpied TGI -Institut Pascal, Clermont-Ferrand, France.
Laurent GuyUrology, Hôpital Gabriel-Montpied, Clermont-Ferrand, France.
Marion TempierNuclear Medicine, CLCC Jean Perrin: Centre Jean Perrin, Clermont-Ferrand, France.
Sophie LevesqueNuclear Medicine, CLCC Jean Perrin: Centre Jean Perrin, Clermont-Ferrand, France.
Alban RevyNuclear Medicine, CLCC Jean Perrin: Centre Jean Perrin, Clermont-Ferrand, France.
Florent CachinNuclear Medicine, CLCC Jean Perrin: Centre Jean Perrin, Clermont-Ferrand, France.
Marion ChanchouNuclear Medicine, CLCC Jean Perrin: Centre Jean Perrin, Clermont-Ferrand, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsWe retrospectively included 30 patients with biochemical recurrence of prostate cancer who had undergone

resultsVPFX-derived series were classified differently but better than standard reconstructions (p < 0.001) using half the data. Q.Clear series were not classified differently using half the signal. Some series were noisy but had no significant effect on lesion detectability (p > 0.05). The SubtlePET® algorithm significantly decreased lesion SUV (p < 0.005) and increased liver background (p < 0.005) and had no substantial effect on the diagnostic performance of each reader.

conclusionWe show that the SubtlePET® can be used for

Indexed as

68Ga PSMA-11Artificial intelligence algorithmBiochemical recurrence of prostate cancerDenoisingImage qualityPET

Identifiers

PMID37231229
PMCPMC10212905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.